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 Chapter 48 
 PACAP as a Potential Biomarker: 
Alterations of PACAP Levels in Human 
Physiological and Pathological Conditions 
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 Abstract  Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuro-
peptide with wide distribution and diverse effects. Its presence has not only been 
revealed in the nervous system and peripheral organs, but also in the blood and other 
biological ﬂ uids. Although PACAP is rapidly cleaved in the blood by peptidases, 
increasing number of evidence has been published in the last 10 years that show 
alterations of PACAP levels in different pathological conditions. The present review 
summarizes results obtained in the human blood and other ﬂ uids under normal, 
physiological and pathological conditions with clinical relevance, such as preg-
nancy and delivery, as well as in several diseases. Most clinical data have been 
obtained so far in neurological diseases, such as Alzheimer’s disease, migraine, 
traumatic brain injury, multiple sclerosis, and cerebral hemorrhage, but some other 
diseases have also been shown to be accompanied by alterations of PACAP levels. 
These results indicate that the altered levels may have diagnostic and/or prognostic 
values in several diseases. 
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 Introduction 
 The pitfalls of neuropeptide measurements in biological samples are well known, 
and it is suggested to use neuropeptide immunoreactivity to describe what we mea-
sure with immunoassay techniques. This situation is further complicated in bio-
logical ﬂ uids: the stable tissue levels of neuropeptides change once the peptides 
enter the circulation and are broken down by peptidases. In addition, different 
pathological conditions and medications inﬂ uence the levels and breakdown of 
peptides. In spite of difﬁ culties and uncertainties, various peptides have been 
implicated as potential biomarkers in human diseases and their measurement in 
biological ﬂ uids have also helped to elucidate their involvement in several disease 
pathomechanisms [ 1 ]. 
 Soon after the isolation of pituitary adenylate cyclase activating polypeptide 
(PACAP) by Miyata et al. [ 2 ], certain effects of PACAP in humans and its local-
ization in different human tissues were described [ 3 ,  4 ]. The source of PACAP in 
the blood is not known with certainty. The most logical sources of circulating 
PACAP are tissues known to contain the highest level of PACAP, such as brain 
and endocrine glands. It has also been described that PACAP levels are 1.5 times 
higher in the mouse serum than in the plasma [ 5 ]. The authors suggested that 
platelets signiﬁ cantly contribute to circulating PACAP [ 5 ]. However, we do not 
know, for example in the case of the brain, how different barriers inﬂ uence the 
passage of the peptide into the blood (see Chap.  25 by Banks). Another important 
issue to take into consideration is the short plasma elimination half-life of the 
peptide (5–10 min), similarly to other members of the VIP–secretin–glucagon–
GHRH peptide family [ 6 ]. 
 PACAP levels have been measured in human blood plasma in several studies. In 
healthy volunteers, plasma PACAP levels showed no difference between radial 
artery, internal or external jugular vein or cubital vein [ 7 ] (Table  48.1 ). In addition 
to the baseline levels, it was shown that continuous infusion of PACAP caused rapid 
increase of plasma PACAP levels, and a rapid decrease after cessation of the infu-
sion in a male patient, while inhalation of the peptide did not lead to increased 
plasma levels [ 6 ,  9 ]. Subsequent reports also demonstrated that intravenous infusion 
in volunteers led to increased plasma levels [ 13 ]. PACAP is cleaved by dipeptidyl- 
peptidase IV (DPP IV), which also cleaves several other peptides. The half-life of 
infused PACAP is estimated to be 3.5 min when infused to healthy young volunteers 
for 20 min [ 8 ], while others suggested a longer half-life of about 5–10 min [ 6 ] 
(Table  48.1 ).
 Increasing evidence shows that plasma PACAP levels and PACAP in several 
other body ﬂ uids change under different physiological and pathological conditions 
and these levels may have diagnostic/prognostic values in certain diseases. The 
present review summarizes data obtained in human blood and other ﬂ uids under 
normal and pathological conditions (summarized in Tables  48.1 ,  48.2 , and  48.3 ).
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 PACAP Levels Under Physiological Conditions 
 PACAP levels under normal circumstances are summarized in Table  48.1 . 
 Early studies measured plasma PACAP levels in rats. A pioneer paper showed that 
the hypohyseal portal blood contained signiﬁ cantly higher PACAP immunoreactivity 
than the peripheral blood, with higher hypophyseal levels in females than in males 
([ 28 ]; 50–100 pmol/l vs. 23–24 pmol/l). This study proved that PACAP was released 
into the hypophyseal portal vessel blood and, therefore, can be regarded as a hypotha-
lamic pituitary regulatory factor, with PACAP38 being the major form [ 28 ]. 
 Pregnancy and Delivery 
 During pregnancy, PACAP levels show a moderate but signiﬁ cant elevation during 
the second and third trimesters compared to earlier gestational periods or nonpregnant 
women [ 10 ]. From the same volunteer population, during delivery, a signiﬁ cant, 
about 70 %, decrease was observed. Levels in the plasma of mothers returned to 
 Table 48.3  Changes in PACAP levels in human non-neurological diseases 
 Condition or disease 
 Patient 
number 
 Sample/ 
method  Level ranges 
 Change of 
PACAP  Reference 
 Chronic hepatitis B 
patients under 
antiviral therapy 
 25 treated, 
22 healthy 
controls 
 Plasma, 
RIA 
 Controls: 65, 
hepatitis: 22 
after treatment: 
49 pg/ml 
 ↓ in hepatitis 
patients, ↑ after 
antiviral therapy 
 [ 25 ] 
 Nephrotic syndrome 
in children 
 28 vs. 10 
controls 
 Plasma, 
urine, 
Western 
blot 
 Results given 
as % of 
controls, 
absolute values 
not available 
 Plasma PACAP 
↓, urinary levels 
↑ in nephrotic 
states 
 [ 26 ] 
 Nephrectomy  3  Plasma, 
 Western 
blot 
 As above  ↑ After 
nephrectomy 
 [ 26 ] 
 Premature ovarian 
failure 
 5 (vs. 13 
controls) 
 Plasma, 
ELISA 
 58 (vs. 136) 
pg/ml 
 ↓  [ 11 ] 
 Idiopathic 
hypogonadotropic 
hypogonadism 
 9 (vs. 13 
controls) 
 Plasma, 
ELISA 
 92 (vs. 136) 
pg/ml 
 ↓  [ 11 ] 
 Superovulation 
treatment 
 132  Follicular, 
ﬂ uid RIA 
 143 fmol/ml 
(28–690 fmol/
ml), cutoff 
value: 
290 fmol/ml 
 Correlation with 
the number of 
retrieved 
oocytes: lower 
levels 
associated with 
higher number 
of oocytes 
 [ 27 ] 
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baseline 3 days after delivery. Plasma levels were also measured in the newborn 
babies of these volunteer mothers. It was found that the levels of PACAP were in the 
same range as in adults in the peripheral blood, but not in the blood obtained from 
the umbilical arteries, where PACAP level was lower [ 10 ]. The levels were higher 
in the umbilical arteries than in the umbilical vein. These ﬁ ndings indicate that 
during pregnancy PACAP is synthesized by the placenta or other maternal tissues in 
higher amounts, possibly necessary for the fetal and/or maternal tissue develop-
ment. The sudden drop during delivery might indicate a role in the uteroplacental 
circulation and/or uterine contraction. The higher level in the umbilical artery 
(carrying venous blood from the fetus) than in the vein (carrying blood from the 
placenta to the fetus) indicates a fetal synthesis of the peptide [ 10 ]. 
 Another study also investigated the level of PACAP in fetal cord blood and new-
born babies [ 12 ]. The authors found no difference between male and female babies 
or between newborns and postmenopausal women between 64 and 83 years. It was 
also found that there was a slightly elevated level after caesarian delivery compared 
to vaginal birth, but there was no difference between PACAP levels in babies whose 
mothers progressed through labor or those who did not [ 12 ]. PACAP levels were 
unrelated to gestational age or Apgar score. The level of PACAP showed a slight 
increasing tendency with increasing birth weight. Based on the function of PACAP 
in stress adaptation and stress responses, it could be hypothesized that PACAP levels 
would differ in perinatal stress, but these data did not support this hypothesis. 
 In contrast to the above-mentioned results, Kanasaki and colleagues showed that 
plasma PACAP levels were lower in pregnant women compared to nonpregnant 
women [ 11 ]. PACAP levels were measured parallel with levels of luteinizing hor-
mones, but no correlation was found between variations in PACAP and gonadotropin 
levels [ 11 ]. 
 Related to pregnancy and childcare, other ﬂ uids also have to be mentioned: 
breast milk, amniotic ﬂ uid, and follicular ﬂ uid. Follicular ﬂ uid contained relatively 
stable levels of PACAP, with PACAP levels correlating with the number of retrieved 
oocytes during hyperstimulation treatment, the details of which are discussed below 
[ 27 ,  29 ]. In the amniotic ﬂ uid, the presence of the unchanged PACAP molecule 
could not be detected by mass spectrometry, but RIA measurements conﬁ rmed 
PACAP-like immunoreactivity (LI) [ 29 ]. These results show that an altered or 
bound form of the peptide was present in the amniotic ﬂ uid, the signiﬁ cance of 
which still awaits further investigation. PACAP levels were markedly higher in the 
breast milk than in the plasma [ 30 ]. This topic is reviewed in a separate chapter 
(Chap.  49 ) of this book by Tamas et al. 
 PACAP Levels Under Pathological Conditions 
 Neurological Diseases 
 Changes in PACAP levels in neurological diseases are summarized in Table  48.2 . 
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 Alzheimer’s Disease 
 In postmortem human brains, Han and coworkers demonstrated a marked reduction 
in PACAP levels in several brain areas of Alzheimer’s disease patients [ 16 ,  17 ]. It 
was found that PACAP levels were reduced in the middle temporal gyrus, superior 
frontal gyrus, entorhinal cortex and primary visual cortex both at the mRNA and 
protein levels. Furthermore, the authors found that PACAP reduction was associated 
with pathological hallmarks of Alzheimer’s disease: PACAP levels were reduced 
with higher amyloid plaque scores in the entorhinal cortex and superior temporal 
gyrus, but not in the primary visual cortex, a region spared in most cases of the 
disease. Levels were lower in advanced Braak stages than in moderate stages. Lower 
PACAP levels were measured in postmortem cisternal cerebrospinal ﬂ uid (CSF) of 
the same patients parallel with the reduced brain tissue levels [ 16 ]. Additionally, 
PACAP concentrations in patients with Alzheimer’s disease strongly correlated 
with the dementia rating scores. The inverse correlation between PACAP and the 
pathological hallmarks of the disease suggests that PACAP is not only reduced in 
Alzheimer’s disease, but also represents the severity of this pathology [ 16 ,  17 ]. 
These data suggest that the strongly reduced neurotrophic effect of PACAP may 
be an important contributing factor to Alzheimer pathology. It supports the obser-
vations made in mouse models of Alzheimer’s disease, where one of the down-
regulated genes important for neuronal survival was PACAP [ 31 ] and PACAP 
levels were strongly reduced in the brains of mutant mice resembling Alzheimer 
pathology [ 17 ]. 
 In a subsequent study, the same research group showed that PACAP decline was 
associated with mild cognitive impairment preceding Alzheimer’s disease in the 
above described brain areas [ 18 ]. It was found that PACAP levels were lower not 
only in the superior frontal gyrus and middle temporal gyrus but also in the CSF 
[ 18 ], although to a lesser extent than in fully developed Alzheimer’s disease. Values 
were inversely correlated with the dementia rating score. These data suggest a pro-
gressive decline of PACAP levels in Alzheimer-related dementias. The expression 
level of the PAC1 receptor was also evaluated and it was shown to be upregulated in 
mild cognitive impairment, but not in fully developed Alzheimer’s disease in the 
superior frontal gyrus [ 18 ]. This implies a transient, possibly compensatory upregu-
lation of PAC1 receptor in mild impairment, which is lost at more progressed states 
[ 18 ]. The authors suggest that CSF PACAP could be a good candidate of disease 
progression marker given the close correlation with disease scores and the speciﬁ city, 
since no reduction was observed in other types of dementia (see below). 
 Other Dementias 
 An early study compared blood levels of several neuropeptides, including that of 
PACAP, in neonatal blood of children with autism spectrum disorder, mental retar-
dation without autism and in children with cerebral palsy [ 19 ]. There was no differ-
ence in PACAP levels between the groups, in contrast to VIP, which showed higher 
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levels in children with autism [ 19 ]. Han and coworkers measured CSF PACAP levels 
not only in Alzheimer’s disease, but also in other types of dementia, such as 
Parkinson’s disease with dementia and frontotemporal lobar degeneration. In con-
trast to the signiﬁ cant reduction observed in Alzheimer’s disease, no reduction was 
observed in the CSF of other dementia patients postmortem [ 16 ]. In a family study, 
where members showed mental retardation, some displaying partial trisomy 18p 
with three copies of the PACAP gene [ 5 ]. It was found that two family members 
with severe mental retardation and accompanying other neurological problems had 
signiﬁ cantly higher level of PACAP, and two members with borderline IQs had 
moderately increased PACAP levels [ 5 ]. 
 Post-traumatic Stress Disorder 
 Regarding the potential use of PACAP as a biomarker in post-traumatic stress 
disorder, a pioneer study was published in 2011 [ 23 ]. The authors found, for the ﬁ rst 
time, that there was a sex-speciﬁ c association of PACAP blood levels with fear 
physiology and stress symptoms in females. Post-traumatic stress disorder symp-
toms signiﬁ cantly correlated with PACAP38 levels in females, but not in males, and 
the disease diagnosis was associated with PACAP levels in females, with higher 
PACAP38 found in the stress-disorder cohort. PACAP38 levels predicted differen-
tial response on the symptoms necessary to fulﬁ ll the criteria in females, like avoid-
ance, hyperarousal, and reexperiencing [ 23 ]. They also found association with gene 
polymorphism of PACAP and PAC1 receptor, reinforced in a number of subsequent 
studies (further discussed in Chap.  45 of this book, by Ressler et al.). 
 Acute Spontaneous Basal Ganglia Hemorrhage 
 A recent study showed that plasma PACAP concentrations were signiﬁ cantly higher 
in patients after acute spontaneous basal ganglia hemorrhage than in healthy control 
subjects [ 14 ]. This study examined a high number of patients: 150 patients with 
stroke and 150 age- and gender-matched control individuals. In addition to elevated 
PACAP levels, a positive association was also shown between PACAP concentra-
tions and neurological score, as well as with hematoma volume. Patients, who died 
within the ﬁ rst week after admission, had higher PACAP levels. A cutoff value was 
identiﬁ ed that predicted 1-week mortality with high sensitivity and speciﬁ city, and 
the predictive value was found to be similar to the neurological scores. Similarly, in 
patients with 6-month survival, elevated PACAP levels were found and it also pre-
dicted mortality with high sensitivity and speciﬁ city. Studying the overall survival, 
plasma PACAP concentration proved to be an independent predictor for overall 
survival similarly to scores and hematoma volumes. Overall survival times were 
signiﬁ cantly shorter in patients with high PACAP levels than those with low con-
centrations [ 14 ]. The authors suggested that PACAP could be a good prognostic 
predictor in hemorrhage patients and hypothesized that the elevated blood PACAP 
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levels may reﬂ ect an overproduction of PACAP as a pathological response to the 
loss of neural tissue in the CNS and it might be associated with the neuroprotective 
effects of the neuropeptide. Another recent study has conﬁ rmed these ﬁ ndings in 
aneurysmal subarachnoid hemorrhage [ 15 ]. These authors examined 118 hemor-
rhage patients and compared them to 118 controls. Hemorrhage patients had signiﬁ -
cantly elevated PACAP levels on admission and plasma PACAP levels were 
independently associated with clinical severity scores. The neuropeptide was identi-
ﬁ ed as an independent predictor of survival [ 15 ], suggesting that PACAP might be 
a potential prognostic biomarker of subarachnoid hemorrhage. 
 Traumatic Brain Injury 
 Our group demonstrated that PACAP could be reliably measured from the human 
CSF (25–80 fmol/ml) [ 24 ]. We measured PACAP levels in the plasma and CSF of 
patients who suffered severe traumatic brain injury. Patients were enrolled with a 
Glasgow Coma Scale ≤ 8 on admission. We detected higher concentrations of 
PACAP in the CSF after traumatic brain injury and both plasma and CSF levels 
increased within the ﬁ rst 24–48 h after the injury. Thereafter, levels stayed high and 
did not increase further. In surviving patients, plasma and CSF levels were parallel, 
possibly indicating a damage in the blood–brain barrier. However, in patients, who 
died within the ﬁ rst week, plasma levels were almost double compared to levels of 
the CSF. There was no correlation with other clinical parameters [ 24 ]. These data 
show a relationship between ﬁ rst week mortality and plasma PACAP levels and sup-
port the possible hypothesis that PACAP levels are upregulated by the peri-injury 
areas, similarly to earlier immunohistochemical data from postmortem brains of 
traumatic brain injury patients [ 32 ]. However, similarly feasible explanation can be 
the relationship between the degree of blood–brain barrier injury and the elevated 
plasma PACAP levels. 
 Multiple Sclerosis 
 The role of PACAP in neuro-inﬂ ammatory processes was proposed on the basis of 
experimental data. Administration of PACAP suppressed experimental autoimmune 
encephalomyelitis, a model of multiple sclerosis [ 33 ]. Studies in mice supported 
these observations by showing that PACAP knockout mice exhibited exacerbated 
encephalomyelitis, thus, the endogenous production of the peptide protects against 
multiple sclerosis, probably by modulating regulatory T cells [ 34 ,  35 ]. A clinical 
study investigated PACAP and VIP levels in the plasma and CSF of multiple sclero-
sis patients [ 22 ]. It was found that PACAP levels decreased in the CSF, while plasma 
PACAP levels did not change. These data suggest that PACAP may inﬂ uence the 
course of multiple sclerosis. 
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 Migraine 
 The role of PACAP in migraine is evidenced both by animal and human studies. 
Due to the strong vasodilatory effect of PACAP and its sensitization function in the 
trigeminovascular system, PACAP is suggested to play an essential role in the 
induction of migraine [ 36 ]. Infusion of PACAP caused headache in healthy patients 
and migraine-like attacks in migraine patients [ 13 ,  37 ]. Animal studies supported 
these observations: PACAP38 was present in the trigeminal ganglion and caudal 
trigeminus nucleus, and plasma PACAP levels increased after electrical stimulation 
of the trigeminal ganglion [ 38 ] or after dural stimulation in cats [ 21 ]. PACAP 
knockout animals showed reduced responses to nitroglycerol [ 39 ]. 
 As far as the plasma levels are concerned, Tuka et al. [ 20 ] found that plasma 
PACAP38 levels were signiﬁ cantly lower in the plasma of migraineurs during the 
interictal period than in healthy subjects, but elevated levels were shown during the 
ictal phase relative to the attack-free periods. In 21 migraineurs, samples were mea-
sured from the same subjects during attack and interictally. It was found that plasma 
PACAP38 levels were signiﬁ cantly higher during the ictal period. A negative 
correlation was observed between the interictal PACAP38 level and the disease 
duration [ 20 ]. Similarly to these data signiﬁ cantly lower plasma PACAP38-LI was 
detected in the inter-bout period of cluster headache patients than in healthy con-
trols. Plasma PACAP38-LI was remarkably elevated during the attack compared to 
the attack-free period of patients (Tuka et al. unpublished observations). These 
results show that PACAP does not only play a role in the pathological mechanisms 
of different types of primary headaches, but its plasma levels are associated with the 
disease and show correlation with the migraine phases [ 40 ,  41 ]. Another recent 
study has further conﬁ rmed the signiﬁ cance of PACAP in the pathogenesis of 
migraine, rather than in tension-type headaches [ 18 ]. The authors conﬁ rmed signiﬁ -
cantly lower interictal levels of PACAP in migraineurs than in healthy controls or in 
tension-type headache patients. Unlike migraineurs, there was no difference in 
PACAP levels between samples from tension-type headache patients and healthy 
controls [ 18 ]. 
 Another study also conﬁ rmed the elevation in PACAP levels during headache 
and lower levels between attacks [ 21 ]. In healthy volunteers, an anti-migraine medi-
cation (sumatriptan) did not lead to any change in circulating PACAP and VIP lev-
els without trigeminovascular stimulation [ 7 ]. However, in migraine patients, 
sumatriptan treatment resulted in decreases in PACAP levels 1 h postinjection [ 21 ]. 
A recent study not only conﬁ rmed that PACAP38 infusion could trigger migraine 
attacks, but also found more increase in plasma PACAP38 levels in patients who 
reported delayed migraine attacks than in those patients who did not have headaches 
after PACAP infusion [ 13 ]. This observation indicates that migraine attacks were 
preceded by elevated plasma levels of PACAP38, similarly to the observation by 
others. The PACAP infusion-induced plasma elevations, in addition, indicate a de 
novo synthesis or release of the peptide. This human study raised interesting points 
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on the source of elevated plasma PACAP levels: PACAP38 infusion to volunteers 
induced elevated plasma PACAP levels only in those patients who reported delayed 
migraine attacks. They found that after 20 min infusion, plasma levels in these 
patients were still elevated after 40 min, which is beyond the 3.5 min half-life of the 
peptide. They suggest that the source of the peptide under normal conditions may 
represent neuronal release from PACAP-ergic nerve terminals. This can be triggered 
in migraine patients, which can result in further elevation [ 13 ]. 
 Other Diseases 
 Changes in PACAP levels in non-neurological diseases are summarized in 
Table  48.3 . 
 Chronic Hepatitis 
 PACAP levels were investigated in patients with chronic hepatitis under oral antivi-
ral therapy (lamivudine) with RIA method [ 25 ]. The authors found no correlation 
between plasma PACAP38 levels and histological ﬁ nding (liver biopsy), serum ala-
nine amino transferase (ALT) level or serum hepatitis B virus -DNA level. However, 
they found that PACAP38 levels were signiﬁ cantly higher in healthy controls than 
in hepatitis B patients at baseline. This decrease was diminished after 52 weeks of 
antiviral therapy: PACAP levels signiﬁ cantly increased in treated patients. The 
authors suggested that the lower PACAP levels observed in hepatitis patients indi-
cated the altered T1/T2 immune responses and related cytokine expression and 1 
year of antiviral therapy could induce a marked amelioration also indicated by 
increased PACAP levels. 
 Nephrotic Syndrome 
 A recent study [ 26 ] has investigated PACAP levels in the plasma and urine in chil-
dren with nephrotic syndrome. It was found that during the nephrotic state, PACAP 
was lost in the urine, compared with non-nephrotic state, when PACAP could not be 
reliably shown in the urine with Western blot. Parallel with the urinary loss, plasma 
PACAP levels decreased during these phases. Together with PACAP, the loss of its 
binding protein, ceruloplasmin, was also lost. These data indicate urinary loss of 
PACAP and its binding protein, thus resulting in a PACAP-deﬁ cient state. This was 
also accompanied by increased megakaryopoiesis and increased platelet aggrega-
tion [ 26 ]. Addition of PACAP inhibited the differentiation of hematopoetic stem 
cells into megakaryocytes during the nephrotic state, while addition of the plasma 
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of congenital nephrotic patients during the nephrotic state directly promoted mega-
karyopoiesis when stem cells of healthy donors were used [ 26 ]. In a few patients, 
plasma PACAP levels were measured after bilateral nephrectomy, when gradually 
increasing levels were found together with decreased platelet count (with a strong 
inverse correlation in congenital nephrotic patients). 
 Gynecological Diseases 
 Lower levels of PACAP were found in patients with premature ovarian failure and 
in patients with idiopathic hypogonadotropic hypogonadism [ 11 ]. PACAP was also 
investigated in the follicular ﬂ uid of women undergoing superovulation treatment, 
where the presence of PACAP was conﬁ rmed with mass spectrometry analysis [ 27 , 
 29 ]. Superovulation treatment is a usual procedure in controlled ovarian hyperstim-
ulation during the in vitro fertilization procedure. After treatment, the number of 
harvested oocytes was recorded. All corresponding PACAP concentrations were 
below 290 fmol/ml in cases when the number of harvested oocytes exceeded 14 per 
patient, while in all cases above this cutoff value, the number of oocytes was below 
14. Thus, lower levels of PACAP might correlate with a markedly higher number of 
ova retrieved and may predict a higher chance for ovarian hyperstimulation, a poten-
tially life-threatening condition from excessive ovarian stimulation [ 27 ]. 
 Concluding Remarks: Future Perspectives and Limitations 
 As summarized in the present review, increasing number of evidence suggests the 
potential clinical use of PACAP as a diagnostic and prognostic biomarker. Numerous 
data have been published in the last few years, showing that it is a rapidly develop-
ing, hot and promising topic. However, several limitations arise at the moment, 
which are brieﬂ y outlined below. 
 Presently we do not know where the PACAP measured in biological ﬂ uids, espe-
cially in the plasma, is exactly derived from. As already mentioned in the introduc-
tory part of this review, the most probable sources are the organs where PACAP 
occurs at high concentrations, like the nervous systems and the endocrine glands. In 
both physiological and pathological situations, PACAP levels in tissues can rapidly 
and drastically change and therefore, the levels measured under those conditions 
may represent PACAP from other sources as well. PACAP is upregulated in the 
central nervous system and peripheral tissues upon several injuries (rev. [ 42 ]). 
Serum PACAP levels have been shown to be increased after sensory nerve stimula-
tion in rats (0.38–0.8 fmol/ml), or superior sagittal sinus stimulation in cats (112–
287 pmol/l) indicating that levels can indeed rapidly change in response to 
physiological or pathological stimuli [ 21 ,  43 ]. In the skin of psoriatic patients, 
PACAP levels showed a 20-fold elevation [ 44 ]. Signiﬁ cantly higher tissue levels 
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were also shown in cardiac tissue obtained from patients with ischemic heart 
disease [ 45 ], while lower levels/downregulation were found in other diseases: in 
lung and colon cancer samples [ 45 ]. In another recent study, no alterations in 
PACAP-LI between healthy and tumoral samples from the urinary bladder and testis 
were detected, but lower PACAP38-LI was found in kidney tumors compared with 
healthy tissue samples, and higher PACAP27-LI in prostatic cancer compared to 
samples from benign prostatic hyperplasia [ 46 ]. These data indicate that PACAP 
levels of different tissue samples are altered under pathological conditions suggest-
ing a potential role of PACAP on tumor growth [ 46 ]. Reduction of PACAP-
containing nerve ﬁ bers was described in a few conditions, such as in women with 
polycystic ovaries [ 47 ]. To what extent these human tissue changes are reﬂ ected in 
alterations of serum PACAP levels is not known at the moment, but animal data 
suggest that acute local changes can cause changes of circulating PACAP as well. 
 Several recent studies have shown alterations in human plasma and other ﬂ uids 
in relation to certain diseases as detailed above. However, the question whether 
PACAP alterations are consequences or contributing factors of the disease still 
remains open [ 17 ]. One possibility is that the triggering cause of a disease leads to 
PACAP decline resulting in a higher vulnerability of the cells, as the neuroprotec-
tive effect of PACAP is reduced. However, it is equally possible that the PACAP 
deﬁ cit—for an unknown reason—predisposes neurons and other cells to certain 
pathological changes [ 17 ]. 
 Several studies suggest that future biomarkers will be used in panels including 
several markers of different sensitivity and speciﬁ city [ 48 ]. Whether PACAP will 
indeed be a biomarker is a question to be answered by future studies, but based on 
our current knowledge it seems that PACAP is a good candidate for certain diseases 
and can be included in a panel of biomarkers after mapping the conditions where 
PACAP alterations are present or absent. 
 One main limitation of the presently available data pool is that we cannot com-
pare results from different laboratories using different methods [ 1 ]. Even the same 
method, but from different manufacturers, can yield non-comparable results. 
Different PACAP antisera developed for immunohistochemistry, RIA or ELISA are 
most of the times not highly speciﬁ c, are directed against different parts of the pep-
tide or the prepro-peptide, in which case other cleavage products might also be 
bound by the antibody. Some authors interpret their results as PACAP- 
immunoreactivity even though the antiserum was developed against prepro-PACAP, 
in other cases the fact that the antiserum was produced against prepro-PACAP is not 
even mentioned in the paper, it only turns out by studying the manufacturer’s 
description. Due to the cleavage by DPPIV, inactive PACAP3-38 and PACAP5-38 
are yielded. The different antibodies used for detection of PACAP may also recog-
nize these inactive forms, so we do not know at the moment whether PACAP- 
immunoreactivity measured in the blood plasma/serum always indicates the active 
peptide. As pointed out by Edvinsson et al. [ 1 ], this mixture of peptide fragments 
also belong to the physiological picture and, therefore, should not be neglected. 
If we use the term “PACAP- or PACAP-LI”, it can cover all these forms. Revealing 
changes in PACAP-like immunoreactivity can yield important results as for the 
biological and pathological signiﬁ cance of the peptide. In addition, PACAP binds to 
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plasma proteins, and the best documented carrier candidate among them is 
 ceruloplasmin [ 49 ]. It has not been clearly demonstrated whether the measured 
PACAP reﬂ ects total, free, and/or protein-bound PACAP. 
 Several further technical limitations limit the comparison of results between 
groups. One of them is the way how human samples are obtained and stored. As 
PACAP is quickly degraded by DPPIV, peptidase inhibitors are required to use. 
However, this is not always indicated in the papers. Some data indicate that PACAP27 
is much more resistant to DPPIV degradation than PACAP38 and therefore has a 
much longer half-life [ 50 ]. Thus, the ratio between the two peptides may also change 
with time, which is not taken into consideration by any clinical report. The different 
anticoagulants used can lead to different values, as shown by Freson et al. [ 5 ]. The 
time passed between sample collection and measurement is also critical. Some authors 
have described PACAP levels in postmortem CSF samples [ 16 ], which obviously can-
not be compared to fresh samples taken from patients. Another issue that needs to be 
taken into consideration is the range within which PACAP levels change. In some 
studies very small changes are signiﬁ cant and authors draw ﬁ nal conclusions, while in 
other studies much bigger alterations are not signiﬁ cant and therefore are interpreted 
as no change. In some studies the sample sizes are very high, with more than a 
hundred involved patients, while in other studies, only a few patients are included in 
one group and even case studies are available with a single patient’s values. 
 One further limitation is the lack of a fast and sensitive analytical method that is 
able to measure PACAP from small sample volumes. In spite of all these factors that 
limit the comparison of data, the alterations within one study can yield valuable 
results showing changes of PACAP levels, which can not only lead to biomarker 
development but can also reveal important functions of PACAP in physiological and 
pathological processes. In order to obtain a solid proof of PACAP as a biomarker, 
multicenter, controlled studies will be necessary in the future, but the growing body 
of evidence for the diagnostic and prognostic value of the peptide summarized in the 
current review justify these efforts. 
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